We analysed 86 patients with CML who received unrelated cord blood transplantation (UCBT), identified through a registry of the Japan Cord Blood Bank Network. At transplantation, the median patient age was 39 years (range, 1-67 years); 38 patients were in chronic phase (CP), 13 in the accelerated phase (AP) and 35 in blast crisis (BC). Median duration from diagnosis to UCBT was 1.5 years (range, 0.2-14.6 years). A nucleated cell (NC) dose of more than 3.0 Â 10 7 per kg was sufficient to achieve neutrophil (91%) and platelet recovery (86%), whereas the lower dose of NC achieved only 60 and 61%, respectively. The duration and type of pre-transplant treatment did not affect neutrophil or platelet recovery. Results of multivariate analysis indicated that older patients (450 years) had a higher incidence of transplant-related mortality. Advanced-disease stage and lower doses of NCs were significantly associated with lower leukaemia-free and event-free survival. At 2-year survival for patients in CP, AP and BC was 71, 59 and 32%, respectively (P ¼ 0.0004). A pre-transplant European Group for Blood and Marrow Transplantation scoring system was effective in predicting the outcome of UCBT. We conclude that UCBT is a reasonable alternative therapy for patients with CML.
Introduction
Recent clinical research on unrelated cord blood transplantation (UCBT) has encouraged the use of human umbilical cord blood (CB) as a source of haematopoietic SCT (HSCT) in patients with haematopoietic malignancies. [1] [2] [3] [4] [5] In Japan, more than 3500 UCBTs have been performed through 11 CB banks in the Japan Cord Blood Bank Network (JCBBN). As a component of quality management and promotion, the JCBBN established a common registry for studying the results of UCBT. However, the clinical application of UCBT for CML has not been established because treatment with interferon (IFN)-a and molecular-targeting reagents, such as imatinib mesylate (imatinib), have induced complete cytogenetic remission and improved long-term survival without the need for allogeneic haematopoietic transplantation. [6] [7] [8] Imatinib has now replaced IFN as the first-line therapy for CML and induces a molecular remission (MR) as well as a complete cytogenetic response (CCyR) in the vast majority of patients newly diagnosed with CML who are in the chronic phase (CP) of the disease. [8] [9] [10] Imatinib induces complete haematological responses not only in patients in CP but also in those in the accelerated phase (AP) of the disease and in blastic crisis (BC). 11 Although its long-term efficacy and feasibility were confirmed in the International Randomized Study of Interferon and STI571 (IRIS), 12 sustained administration of IFN is recommended for preventing disease progression and recurrence from minimal residual disease, which cannot be readily eradicated by imatinib alone. 13, 14 Some patients who show point mutations in the BCR-ABL oncogene are resistant to imatinib, 15 and might also be resistant to the new derivatives, dasatinib and nilotinib. [16] [17] [18] [19] Patients who are resistant to IFN or imatinib may be candidates for HSCT. Both BMT and PBSC transplantation have provided reasonable results in the patients, even in those who were treated with IFN or imatinib before transplantation. 20, 21 Furthermore, minimal residual clones of Ph1 were eradicated by post-HSCT donor lymphocyte infusion. 22, 23 Use of UCBT in patients with CML was first reported by Rubinstein et al. 3 in the context of haematopoietic malignancies. CML appeared to fall into the group of diseases deemed unfavourable for the application of UCBT because of relatively higher graft failure; however, Sanz et al. 24 reported in 2001 that all seven evaluable cases engrafted and four patients with CML-CP remained alive with MR for more than one and a half years.
To address whether patients with CML can be considered applicants for UCBT and to clarify the prognostic factors for UCBT, we analysed 86 registry-based patients with CML who underwent UCBT as the initial HSCT through JCBBN. Our results suggest that UCBT, using an adequate dose of nucleated cells (NCs), may be considered a reasonable therapeutic option for patients with CML, regardless of the duration of treatment.
Patients, materials and methods

Patient selection criteria
Only patients recorded at the JCBBN registry as having undergone UCBT for CML were included in this study. Eighty-six patients who received UCBT as the initial HSCT were analysed. They received UCBT from 1997 to 2006 at CBT centres in Japan. Informed consent was provided according to the Declaration of Helsinki.
Patient characteristics
The characteristics of the 86 patients are listed in Table 1 . Median age was 39 years (range, 1-69 years), including 9 children (1-15 years), 58 young adults (16-50 years) and 19 older adults (51 or older). Median weight was 58.3 kg (range, 9-96.1 kg). At UCBT, 38 patients were in CP (7 in first CP, 29 in second CP, 2 in third or subsequent CP), 13 patients were in AP (9 in first AP, 3 in second AP and 1 in third or subsequent AP) and 35 patients were in BC (23 in first BC, 11 in second BC and 1 in third or subsequent BC). A higher percentage of the older adults had advanced stages of the disease compared to the children (P ¼ 0.03). In the 19 older adults, only 4 (21%) were in CP, 5 (26%) were in AP and 10 (53%) were in BC; in the 58 young adults, 29 (50%) were in CP, 5 (8.6%) were in AP and 24 (41.4%) were in BC. In contrast, of the nine children, five (56%) were in CP, three (33%) were in AP and one (11%) was in BC at CBT. Patients received transplants at a median time of 1.96 years (range, 0.18-17 years) after they were diagnosed with CML. Sixteen had received chemotherapy Umbilical cord blood characteristics and transplantation procedure The CB cells were processed and cryopreserved in the cell processing and cryopreservation facilities of 11 public CB banks in Japan. The CB cells were initially processed using hydroxyl ethyl starch (HES) 25 and cryopreserved according to the technical and quality management guidelines of the JCBBN.
The CB characteristics are shown in Table 2 . NC dose before cryopreservation was performed for all patients, but the number of GM colony-forming units (GM colonies) and CD34 þ cells dose were available only for 78 and 77 patients, respectively. HLA antigen disparities were categorized as either GVHD or rejection direction (Table 2) . Low-resolution antigens of HLA-A, -B and -D were identified for all patients by serologic typing. HLA-DRB1 alleles were determined by high-resolution molecular typing using the sequencing-based HLA typing method in 81 of 86 cases. Patients without either an available family donor or an unrelated bone marrow donor were eligible for CBT, when two or less than two antigen mismatched HLA CB units were available.
Conditioning and GVHD prophylaxis regimens varied among the centres. Briefly, the conditioning regimen consisted of myeloablative therapy in 66 cases, reduced intensity in 18 cases and miscellaneous chemotherapy in 2 cases. The myeloablative-conditioning regimen included TBI-containing regimens (TBIX8 Gy) or conventional high-dose chemotherapies with CY (X120 mg kg
À1
). G-CSF was administered until engraftment in 80 cases, whereas no cytokine was administered in 6 cases. For GVHD prophylaxis, patients received CsA-, tacrolimus-or mycophenolate mofetil-based regimen, except one patient, who received no prophylaxis ( Table 2) .
Statistical methods
The median duration of follow-up was 24 months (range, 3-67 months). The outcome end points were neutrophil recovery, platelet recovery, GVHD, relapse, transplantrelated mortality (TRM), overall survival (OS), leukaemiafree survival (LFS) and event-free survival (EFS). The definitions of the statistical models used were in accordance with the Statistical guidelines for European Group for Blood and Marrow Transplantation (EBMT, http:// www.ebmt.org/1WhatisEBMT/whatisebmt2.html). Neutrophil recovery was defined by an ANC of at least 0.5 Â 10 9 per liter for 3 consecutive days, the first being used as the recovery day. Platelet recovery was defined by a nontransfused platelet count of at least 20 Â 10 9 liter for 3 consecutive days. Deaths occurring before day 90 or 180 were considered as competing risks for neutrophil or platelet recovery, respectively. The graft failure rate for neutrophils was calculated for patients living without relapse for more than 90 days. Acute and chronic GVHD were diagnosed and graded at each centre according to the standard criteria. 26 Relapse was defined on the basis of the reappearance of the blast or Ph1 chromosome or BCR-ABL transgene by cytogenetic and/or molecular analysis, including PCR and FISH. TRM was considered a sole cause of non-leukaemic deaths occurring after transplantation; OS was defined as the time between transplantation and death due to any cause; LFS was defined as the time interval from UCBT to a first event, either relapse or death, in patients achievingCR; and EFS was defined as the time interval from UCBT to a first event, either diagnosis of graft failure, relapse or death, in patients achieving CR.
Kaplan-Meier estimates provided approximations of incidence over time for OS, LFS and EFS, whereas Cox models were used to evaluate the combined influence of patient-, CB cell dose-, disease-and transplant-related variables on the outcome. The end points of neutrophil and platelet recovery, acute and chronic GVHD, relapse and TRM were analysed using cumulative incidence curves that estimated incidence according to the Fine and Gray models, in which we first used univariate models that contained each of the variables one at a time. Then all variables with a Po0.05 by the likelihood-ratio test were included in a multivariate model. Cause-specific hazard ratios were estimated with 95% confidence intervals (CIs). 27 Statistical analysis was performed with the R Foundation version 2.5.1 (http://www.r-project.org/) and JMP version 6.0.2 software packages (SAS Institute, Cary, NC, USA).
Results
Neutrophil and platelet recovery
The cumulative incidence of neutrophil recovery on day 90 was 68% (95% CI, 58-78%; Figure 1a ). During the first 90 days after transplantation, the competing risk for neutrophil recovery was death (n ¼ 16). The graft-failure rate for neutrophil recovery was 17% (12 of 70 living patients). For those patients who recovered, the median time to achieve an ANC equal to or greater than 0.5 Â 10 9 per liter was 24 days (range, 6-78 days). The cumulative incidence of neutrophil recovery on day 90 was 91% (95% CI, 77-100%) for the patients who received more than 3.0 Â 10 7 per kg NCs before cryopreservation, and 60% (95% CI, 48-72%) for those who received a lower dose of NCs (P ¼ 0.00005; Figure 1b) . With respect to the dose of GM colonies before cryopreservation, the cumulative incidence of neutrophil recovery was 83% (95% CI, 70-100%) for patients who received more than 25 Â 10 3 per kg of GM colonies and 62.0% (95% CI, 49-75%) for those who received a lower dose (n ¼ 79, P ¼ 0.025; Figure 1c ). The association of neutrophil recovery with the dose of CD34 þ cells before cryopreservation, the rejection-directed disparities of HLA antigens in low and high resolution, disease status at UCBT and type of conditioning regimen (that is, myeloablative or not) was not statistically significant. Note that no statistical significance was found in the association of neutrophil recovery with type of pretreatment (IFN vs imatinib), or with the duration from diagnosis to UCBT (1 year or less vs Unrelated CBT for CML T Nagamura-Inoue et al longer), as shown in Figure 1d . In a multivariate analysis, only dose of NCs before cryopreservation at greater than 3.0 Â 10 7 per kg was associated with improved neutrophil recovery (Table 3) .
On day 180, cumulative incidence of platelet recovery, as indicated by more than 2 Â 10 10 per liter of platelets in blood, was 69% (95% CI, 59-79%; Figure 2a) . During the first 180 days after transplantation, the competing risk for platelet recovery was death (n ¼ 16). For those patients who recovered, the median time to achieve platelet recovery was 42 days (range, 26-148 days). In the univariate analysis, the factors statistically associated with platelet recovery were the dose of NC and GM colonies before cryopreservation (Figures 2b and c) . On day 180, the incidence of platelet recovery was 86% (95% CI, 76-100%) for the patients who received more than 3.0 Â 10 7 per kg NCs compared to 61% (95% CI, 49-73%) for those who received a lower dose (P ¼ 0.00002). Additionally, the incidence of platelet recovery was 83% (95% CI, 66-100%) for patients who received more than 25 Â 10 3 per kg of GM colonies, whereas it was 63% (95% CI, 50-76%) in those who received fewer (P ¼ 0.0062). No statistical significance was found in the association of platelet recovery with dose of CD34 þ cells, HLA disparities, type of pretreatment or duration from diagnosis to UCBT. Multivariate analysis demonstrated that NC dose was the only factor significantly influenced by platelet recovery (Table 3) .
Acute and chronic GVHD Acute GVHD was observed in 38 of the 58 living patients with neutrophil engraftment (13 had grade I; 18, grade II; 5, grade III; 2, grade IV), whereas 20 had no acute GVHD. The cumulative incidence of acute GVHD at grade II or higher before day 100 was 47% (95% CI, 36-58%). We did not find a statistical association of HLA (AB-DRB1) disparities in a GVHD direction with the incidence of acute GVHD, although a trend towards a lower incidence of severe, acute GVHD was observed in less mismatched transplants. Chronic GVHD was found in 15 of the 57 patients who were alive and obtained engraftment (13 with limited disease; 2 with extensive disease).
TRM and cause of death
The respective 100-day and 1-year cumulative incidences of TRM were 20% (95% CI, 11-29%) and 25% (95% CI, 16-34%), respectively. When we separated the three age groups including children, young adults and older adults, the incidence of TRM in children was comparable to that in the young adults. The cumulative incidence of TRM at 1 year was 11% (95% CI, 0-33%) in children, 20% (95% CI, 9-30%) in young adults and 49% (95% CI, 25-73%) in older adults (P ¼ 0.026). No significant difference was observed in TRM incidence by regimen (myeloablative (23%) vs reduced-intensity regimen (26%), P ¼ 0.5). Even though the older-adults group received a greater percentage of the reduced-intensity regimen (12 patients with reducedintensity and 7 patients with the myeloablative regimen), our data showed that old age (51 years or older) had a significant influence on the TRM. The cumulative incidence of TRM in older adults at 1 year was 49 ± 24, and 18 ± 10% in those younger than 50 years of age (P ¼ 0.0086; Figure 3a ). The cumulative incidence of TRM by disease stage at UCBT was 34 ± 16% in BC, 16 ± 21% in AP and 8 ± 9% in CP (P ¼ 0.019; Figure 3b) . Results of the multivariate analyses showed that older age and the dose of GM colonies were factors associated with a significantly increased risk of TRM. The disease stage at UCBT was only marginally associated with an increased risk of TRM (Table 3) . A total of 38 patients died and their causes of death are shown in Table 4 . Five patients died of GVHD-related complications, two of veno-occlusive disease, two of bleeding, nine of infectious complications (bacterial, five; bacteria plus fungus, one; fungus, one; tuberculosis, one; viral encephalitis, one), one of tacrolimus-related encephalopathy and seven of graft failure-related complications. In total, ten patients died of relapse or induction failure, and one died of TRM after a second UCBT to treat the relapse. One patient died of the original malignancy, colon cancer.
Relapse incidence
In total, 29 patients had cytogenetic, molecular and/or haematological relapse after UCBT, as defined in Patients, materials and methods. The 2-year cumulative relapse incidence was 37% (95% CI, 26-48%). The only factor significantly associated with increased relapse incidence was NC-dose before cryopreservation of less than 3.0 Â 10 7 per kg (44±13 vs 9±12%; P ¼ 0.01; Figure 3c ). Patients with an advanced stage (AP and BC) of disease at transplantation showed a trend towards earlier relapse compared to those in CP at transplantation; however, no significant difference was observed 1 year after UCBT (Figure 3d) .
In 29 patients who relapsed after CBT, 21 relapsed haematologically, whereas 8 patients had a molecular/ cytogenetic relapse. In total 3 of the 21 patients with haematological relapse received the second HSCT; others received chemotherapy and/or STI or IFN. Five patients achieved haematological remission while still alive, but 15 died of relapse or of the second HSCT-related mortality. Among eight patients with molecular/cytogenetic relapse (one in first CP, six in second CP and one in second AP at the time of CBT), three patients received STI, two chemotherapy and one STI and chemotherapy, when minimal residual disease was found. Only two patients developed into haematological relapse, whereas the others continued in remission.
Event-free, leukaemia-free and overall survival Estimated 2-year EFS, LFS and OS were 34±6, 38±6 and 53 ± 6%, respectively (Figure 4a) . Results of univariate and multivariate analyses showed that the disease stage at UCBT significantly influenced the LFS, EFS and OS (Table 3) . Two-year LFS was 52% (95% CI, 37-73%) for patients in CP at the time of transplantation, 38% (95% Unrelated CBT for CML T Nagamura-Inoue et al CI, 17-84%) for those in AP and 22% (95% CI, 10-48%) for those in BC (P ¼ 0.0004; Figure 4b ). The probability of 2-year OS for patients in CP, AP and BC was 71% (95% CI, 56-90%), 59% (95% CI, 37-94%) and 32% (95% CI, 20-55%), respectively (P ¼ 0.0004; Figure 4e ). The probability of survival remained higher for the patients in CP to AP at UCBT compared to LFS because the molecular or cytogenetic relapse in CP or AP might not be fatal. Note that NC-dose before cryopreservation also significantly affected the LFS and EFS (Table 3) . Two-year EFS was 20% (95% CI, 12-35%) for the patients who received less than 3.0 Â 10 7 per kg NCs before cryopreservation, whereas it was 68% (95% CI, 48-96%) for those who received more than 3.0 Â 10 7 per kg NCs (P ¼ 0.0005; Figure 4c ). A marginally significant influence on 2-year EFS was observed if a patient was in the youngest age group (74; 95% CI, 48-100%) compared to those of young adults (33; 95% CI, 22-49%) and older adults (15; 95% CI, 3-72%; P ¼ 0.049; Figure 4d ). Hence, no significant influence by age was found in multivariate analysis for LFS, EFS and overall survival.
Pre-transplant risk scoring system of EBMT and TRM, LFS and OS The pre-transplant risk scoring system was established by the EBMT to evaluate patients with CML who are candidates for HSCT. 28, 29 We adjusted the data of the patients enrolled in the JCBBN to conform to the EBMT scoring system. The scores of all patients were raised by one point because of unrelated donors. When the EBMT scoring system was applied, 1 had a score of 1, 10 had scores of 3, 18 had scores of 4, 25 had scores of 5, 21 had scores of 6 and 10 had scores of 7 ( Table 1 ). The outcome of TRM and survival had a tendency to be correlated with the pre-transplant scores. We compared the patients with scores of 0-4 (n ¼ 30) vs the patients with scores of 5-7 (n ¼ 56). The patients with a score of 5-7 had a significantly higher incidence of TRM and an unfavourable survival rate. The 1-year cumulative incidences of TRM were 7% (95% CI, 0-16%) for the patients with a score of 0-4 and 34% (95% CI, 21-47%) for those with a score of 5-7 (P ¼ 0.005; Figure 5a ). The 2-year survival rate was 66% (95% CI, 48-89%) for patients with a score of 0-4 and 47% (95% CI, 35-63%) for those with a score of 5-7 ( Figure 5b ).
Discussion
Reports of UCBT in patients with CML are limited. Sanz et al. 24 reported on nine cases from a single institute, but the remaining cases were reported only as part of a heterogeneous series of patients with different diseases 3 or as anecdotal case studies. To our knowledge, this retrospective registry-based analysis is the first that was specifically designed to describe the results of UCBT in patients with CML.
As expected, administering higher doses of NC and GM colonies before cryopreservation produced significantly quicker and more effective myeloid and platelet engraftment; however, the dose of GM colonies was not statistically significant because of missing data. Patients (14 adults and 8 children) who received more than 3.0 Â 10 7 per kg NCs achieved the most successful myeloid and platelet engraftments. On the basis of these data, adult patients and their physicians are encouraged to obtain units containing a higher NC count. In contrast to previous studies, 30, 31 CD34 þ cells did not have a significant influence on the incidence of myeloid engraftment. As with the dose of GM colonies, CD34 þ cell data were missing for several patients and different assay systems for CD34 þ analysis were used in each bank. Engraftment was influenced neither by duration from diagnosis to UCBT nor by prior therapy for CML. The patient with the longest duration from diagnosis to UCBT (17.6 years) achieved successful engraftment. Although the disease stage of CML at UCBT tended to influence the engraftment rate, no significant difference was detected (data not shown; P ¼ 0.08). These results are encouraging for patients with CML who are treated with imatinib or IFN before UCBT.
As expected, we found that an advanced disease stage at UCBT was significantly associated with lower LFS, EFS and OS. Moreover, although the disease stage of CML at UCBT did not have a significant influence on the cumulative incidence of relapse, it seemed to influence TRM (Figure 3b ). However, in the multivariate analysis, the only significant factors that influenced higher TRM were age of 50 years or older and dose of GM colonies at less than 25 Â 10 3 per kg ( Table 3 ). The collinearity between older age and advanced stage of the disease may have had a large influence on this part of the analysis. In comparison to previous studies on unrelated BMT, [32] [33] [34] OS in UCBT seemed comparable to that in unrelated BMT. Two-year survival rates varied approximately 44-77% for patients in CP with unrelated BMT, whereas a 71% survival rate was observed for those in CP with UCBT. The finding that young age (1-15 years) indicated high EFS (74% at 2 years) with only marginal significance by univariate, but not by multivariate, analysis may have occurred because children included a relatively low percentage of the advanced disease cohort at CBT and a relatively high dose of NCs compared to the adults. Note that an NC dose higher than 3.0 Â 10 7 per kg before cryopreservation improved the outcome of myeloid and platelet engraftment, the relapse rate and LFS. Dini et al. 35 reported that a NC dose higher than 3 Â 10 8
per kg was associated with LFS in unrelated BMT, although the NC dose in UCBT was one log less than in UBMT; however, the dose of GM colonies did not influence the relapse and DFS. This discrepancy in the influence of the dose of GM colonies on engraftment and relapse suggests that non-myeloid stem cells in NC, such as T cells, are important in the immune system after HSCT. 36 The most likely causes of death in UCBT for patients with CML were related to transplantation rather than relapse. The high incidence of rejection-related complications, such as infections and bleeding, remains to be resolved; however, unexpectedly, the incidence of GVHD as the cause of death was relatively higher in UCBT. CML is the only haematopoietic malignancy shown to respond effectively to immunotherapy with donor lymphocyte infusion after allogeneic HSCT. 22, 23 Some unintended factors by physicians might promote the development of GVHD, although we could not assess this concern in detail in this retrospective registry-based analysis. To clarify this important issue, carefully designed prospective trials are needed.
We also demonstrated that the pre-transplant risk scoring system established by the EBMT for CML 28 can be used to predict overall risk for UCBT. This scoring system is based on previously reported pre-transplant risk factors including histocompatibility, disease stage at the time of transplantation, age and sex of the donor and recipient and time from diagnosis to transplantation. According to this scoring system, we classified the patients using a 7-level risk score. Although a greater number of patients are needed to properly evaluate this scoring system, the group that scored 0-4 showed significantly better LFS, OS and TRM compared to the group that scored 5-7, but the TRM of the higher scoring group was much lower (40%) compared to a previous report (75%). 28 The lower TRM we observed may explain why advanced GVHD was limited and why imatinib, not intensive chemotherapy, was initiated prior to CBT. 37 This scoring system might provide a rational basis for counselling before UCBT as well as other HSCT; however, it does not address donor-side haematopoietic unit data, which is absolutely essential in the selection of CB.
The finding that the duration from diagnosis to UCBT did not affect the main outcome encouraged us to use targeted therapy, such as imatinib, even for patients with advanced-stage CML before transplantation. Furthermore, the patients with cytogenetic/molecular relapse after CBT could be started on imatinib therapy as we describe in this study. Recent evidence suggests that kinase inhibitors, such as imatinib, suppress T-cell functions and immunoglobulin production by B cells. 38, 39 At present, how long patients will need to take imatinib is unclear, but the combination of imatinib and HSCT clearly results in improved survival in patients with CML.
We conclude that UCBT is an encouraging alternative treatment for patients with CML who do not have an identical sibling and/or those who cannot be expected to obtain a favourable cytogenetic response with imatinib treatment. Unrelated CBT for CML T Nagamura-Inoue et al
